About us

Who we are

At PACE Clinical, headquartered in the Netherlands, we are redefining what’s possible in patient adherence—both in clinical trials and real-world healthcare settings. Our mission is to tackle one of the most urgent and costly challenges in healthcare: patient non-adherence to treatment. Through cutting-edge, behavior-driven software and expert consultancy, we empower patients, clinicians, and research sponsors to achieve better health outcomes and generate more reliable clinical data.

Our innovative Adherence Risk Management (ARM) solutions are designed to elevate patient engagement and adherence at every step. By boosting patient well-being and optimizing clinical outcomes, we help lower drug development costs and accelerate the delivery of life-changing therapies. For pharmaceutical sponsors, this means a stronger return on investment and greater confidence in the integrity of clinical trial data.

As the healthcare sector rapidly evolves—with growing demand for real-world evidence and patient-centric solutions—PACE Clinical stands at the forefront. We offer a robust software-as-a-service platform, paired with bespoke consultancy, that not only meets today’s challenges but is agile enough to adapt to tomorrow’s needs. Our approach delivers scalable value and sustained growth for our partners and clients.

What truly sets PACE Clinical apart is our fusion of behavioral science and a deep, patient-centered perspective. Our ARM solutions integrate the latest advances from the BEAMER project and the Subjective Health Experience (SHE) model, enabling us to predict, and improve adherence behavior. This empowers pharmaceutical and medical device companies to achieve more successful clinical development and market launches—ultimately improving lives across society.

Mission Statement

At PACE Clinical, we believe that patient adherence is the key to unlocking true progress in healthcare. Non-adherence isn’t just a statistic—it’s a challenge that affects individuals, families, and entire communities. When patients struggle to follow prescribed therapies, the consequences reach far beyond personal health, driving up drug development costs and limiting the effectiveness of medical innovations.

Our mission is deeply personal:

• We strive to dramatically reduce the impact of treatment non-adherence for patients, their loved ones, and society.
• By delivering innovative, behavior-driven software and expert consulting, we empower the pharmaceutical and healthcare industries to achieve lasting health benefits.
• We elevate adherence in both clinical research and real-world care, ensuring that medical advances translate into tangible improvements for everyone.
• Above all, we aim to create a healthier, more resilient society—helping people recover faster, easing the burden of avoidable health issues, and building a brighter future for all.

Our leadership team brings together decades of experience and a shared passion for making a meaningful difference—as professionals, parents, and future patients. We are personally invested in this mission, working every day to improve lives and strengthen communities worldwide.

Pioneering Patient Adherence

PACE Clinical emerged from a visionary split-off from Link2Trials and a strategic alliance with Forward Faster AI, setting the stage for a company dedicated to transforming patient adherence through innovation and collaboration.

Since 2017, Link2Trials laid the foundation for breakthrough adherence science, leading to the creation of the Adherence Risk Management (ARM) methodology and its robust digital platform. As ARM evolved into a globally recognized solution, the need for a specialized organization became clear—sparking the launch of PACE Clinical, focused on advancing behavioral-based adherence strategies in both clinical research and real-world care.

Partnering with Forward Faster AI, a leader in behavioral modeling and AI-driven digital interventions, PACE Clinical combines scientific rigor with innovative momentum. Together, we are redefining what’s possible in adherence management, driving lasting change for patients, providers, and healthcare systems worldwide.

Team

{{TEAM}}

Our involvement in the BEAMER project

At PACE Clinical, we’re leading a new era in patient adherence for clinical trials and healthcare. Since 2021, our team—building on the foundation of Link2Trials—has played a pivotal role in the BEAMER project, a landmark European initiative dedicated to transforming how patients follow treatment plans across diverse healthcare settings.

Backed by an €11.8 million grant from the Innovative Medicines Initiative, BEAMER brings together twenty-nine top partners from academia, industry, and civil society. Together, we’re developing B-COMPASS, a powerful model that uncovers the behavioral drivers behind treatment adherence. By combining the SHE framework with new insights into health consciousness, personal concerns, and health priorities, B-COMPASS empowers healthcare professionals to predict and support patient adherence with unprecedented precision.

“The Innovative Medicines Initiative 2 Joint Undertaking (IMI2), a public-private partnership between the European Union (EU) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) under the Horizon 2020 program, and IMI associated partner Link2Trials approved the BEAMER8 project (grant agreement number 101034369) with the aim of improving patient support and treatment adherence.”

(Show text between quotes with the EU, IMI, EFPIA and PACE logos under the text in a box)

The breakthroughs from BEAMER are seamlessly integrated into our Adherence Risk Management (ARM) services, keeping our solutions at the cutting edge of science and technology. As validation studies progress, we’re committed to using the best models—whether SHE or B-COMPASS—to maximize positive outcomes for patients and the broader healthcare community.

In the BEAMER project the following companies and organizations are actively involved: